New Cancer Test Predicts Risk

Aureon Laboratories has introduced a first-of-its-kind test that uses biopsy tissue to predict the progression of prostate cancer and likelihood of its recurrence. The Prostate Px+ measures the clinical, anatomical, and molecular features present in men who are newly diagnosed with the disease, allowing for more informed and personalized treatment planning.

For more information about research on prostate cancer, go to capcure.org.